Table 2.
Summary (number subjects (% of total in each group)) of adverse events reported
| Days 1–42: Treatment with lamotrigine or placebo | |||
|---|---|---|---|
| Study group Drug exposure | LTG + OLZ (n = 19) Lamotrigine | LTG (n = 13) Lamotrigine | OLZ (n = 20) Placebo |
| Headache | 3 (15%) | 3 (23%) | 5 (25%) |
| Dizziness | 0 | 1 (8%) | 0 |
| Fatigue | 0 | 0 | 1 (5%) |
| Abnormal transaminases | 0 | 0 | 0 |
| Days 43–56: Treatment with lamotrigine and olanzapine, lamotrigine and placebo, or placebo and olanzapine | |||
| Study group Drug exposure | LTG + OLZ (n = 16) Lamotrigine and olanzapine | LTG (n = 12) Lamotrigine | OLZ (n = 18) Olanzapine |
| Headache | 2 (13%) | 4 (31%) | 1 (6%) |
| Dizziness | 4 (25%) | 0 | 6 (33%) |
| Fatigue | 7 (44%) | 3 (23%) | 9 (50%) |
| Abnormal transaminases | 8 (50%) | 0 | 8 (44%) |